Abstracts and Further Information
Franz Faupel received his Ph.D. in physics from the Göttingen University in 1985. He was postdoctoral fellow at the IBM Th. J. Watson Research Center in Yorktown Heights, and got his habilitation from Göttingen University in 1992. Since 1994, he holds the Chair for Multicomponent Materials at Kiel University. Faupel, inter alia, is Chairman of the North German Initiative Nanotechnology and has been serving on several editorial boards including Materials, SN Applied Sciences, Journal of Materials Research, Applied Physics Letters, and Journal of Applied Physics. He was also member of Minerva-Weizmann Committee of the Max Planck Society and Dean of the Faculty of Engineering. He published more than 350 peer reviewed papers on functional nanocomposites, diffusion, glass transition, metallic glasses, plasma deposition, magnetoelectric sensors, metal-polymer interfaces, and other subjects.
Website
Magnetic nanoparticles in diagnostics and therapy
The presentation will provide a brief overview of recent developments in magnetic particle imaging (MPI), a novel imaging method. Using various static and oscillating magnetic fields and tracer materials made of iron oxide nanoparticles, MPI can perform background free measurements of the local concentration of the particles. The method takes advantage of the nonlinear remagnetization behavior of the particles and has the potential to outperform current methods for the detection of iron oxide in terms of sensitivity and spatio-temporal resolution. Starting with an introduction to the relevant physics of nanoparticle magnetization, the design of an imaging device, the evaluation of image quality, the force effect of the magnetic fields and first preclinical results are discussed.
Thorsten M. Buzug was born in Lübeck, Germany. He received his Ph.D. in 1993 in Applied Physics from the Christian-Albrechts-University of Kiel, Germany, where he worked in the field of signal processing applied to chaotic systems. From 1993 to 1994 he had a postdoctoral position at the German Federal Armed Forces Underwater Acoustics and Marine Geophysics Research Institute, where he worked on image acquisition and processing techniques for SONAR applications. In the end of 1994 he joined the Philips Research Laboratories Hamburg, Germany. He was the leader of the Philips Research Cluster Medical Image Processing and responsible for several projects in that field. In October 1998 he has been appointed as professor of Physics and Medical Engineering at the RheinAhrCampus Remagen. 2000-2004 he was head of the Academic Development Committee of the RheinAhrCampus Remagen. 2004-2006 he was head of the Joint Council of Campus Departments.
In December 2006 he became Director of the Institute of Medical Engeneering at the University of Luebeck. 2011 - 2016 he served as Vice-President of the University of Luebeck.
He has published numerous journal articles, conference papers and books. He is member of the National Academy of Science and Engineering (acatech), German Physical Society (DPG), German Society of Biomedical Engineering (DGBMT), German Society of Nondestructive Testing (DGfZP), the IEEE and SPIE.
Website
Fluorescent and magnetic nanoparticles for diagnosis and therapy
Nasschemisch hergestellte Nanopartikel haben ein großes Potenzial für die medizinische Bildgebung und gezielte Wirkstoffdarreichung. Der Vortrag gibt einen Überblick über Vor- und Nachteile magnetischer, plasmonischer und fluoreszenter Partikel. Ein Schwerpunkt ist die biokompatible Oberflächenbeschichtung, mit der Größe, Zeta-Potenzial, Konjugation mit biologischen Erkennungsmolekülen, Zellaufnahme und Bluthalbwertszeit gezielt eingestellt werden kann. Ein weiterer Teil des Vortrages behandelt die Verwendung der Partikel zur gezielten Wirkstoffdarreichung. Am Beispiel von Autoimmunkrankheiten wird gezeigt, wie funktionalisierte SPIONs die Produktion von autoregulatorischen T-Zellen stimulieren und so zur Behandlung von Multiple Sklerose eingesetzt werden können.
Nach seiner Promotion startete Horst Weller 1983 seine Arbeiten zu kolloidalen Nanopartikel am Hahn-Meitner-Institut in Berlin und habilitierte 1993 an der TU-Berlin. 1994 übernahm er in Hamburg einen Lehrstuhl im Institut für Physikalische Chemie. 2006 wurde er Geschäftsführer des Centrums für angewandte Nanotechnologie, welche 2018 in die Fraunhofer-Gesellschaft integriert wurde und welches er bis heute leitet. Er ist Gründungsmitglied der Akademie der Wissenschaft in Hamburg und Co-Sprecher des Bundesexzellenzclusters CUI: Advanced Imaging of Matter.
Website
Nanoparticles in Cardiovascular Medicine
See more get more! Nanoparticles for diagnostic imaging: from lab to market
nanoPET Pharma GmbH is a biopharmaceutical company based in Berlin, specializing in the R&D, production and marketing&sales of innovative agents for diagnostic imaging. The company offers a comprehensive portfolio of preclinical imaging agents under the brand name ViscoverTM covering the principal diagnostic modalities (MRI, CT, US, OI). With more than 20 years of experience in diagnostic imaging, we strive to meet customer demand for sophisticated imaging agents and offer custom solutions including agent development, pharmaceutical manufacturing as well as experimental design.
Our agents differ not only in their chemical composition but also in their morphologies (nanoparticles, emulsions, polymers, small molecules). Different types of morphologies potentially enable varying in vivo pharmacokinetics, resulting in different biodistribution patterns and, thus, improved visualization of various anatomical structures. Hereby, nanoparticles offer exciting opportunities and thus, have been under research and development at our company for a variety of applications ranging from personalized molecular diagnostic imaging to the field of standards and norms.
Nicole Gehrke receiced a diploma degree (Physical Chemistry) from the Technical University of Berlin (Germany) in 2003 (Thesis on "Smart Microgels"). She completed her PhD studies at the Max Planck Institute of Colloids and Interfaces, Golm in 2006 (PhD Thesis: "Biomineralization of mother-of-pearl": Physiochemistry. Exploring and applying principles of biomineralization, e.g. of mother-of-pearl. Synthesis of "artificial mother-of-pearl", e.g. for new materials with the outstanding properties of biomineral materials). 2006-2009 she worked for Schering AG, then Bayer Schering Pharma AG; contrast media research (various Research projects, e.g. on target-specific iron oxide nanoparticles as contrast agents for molecular MRI imaging). Since 2009 Nicole Gehrke works at nanoPET Pharma GmbH as Product Manager: R&D and Marketing & Sales of contrast media for preclinical applications. Imaging: "VISCOVERTM"; research projects and cooperations (B2B and B2C) in the field of preclinical diagnostic imaging and translational approaches).
Website
New data, new insights: new routes for in-vivo tracking
Advanced X-ray fluorescence Imaging provides new insights for preclinical R&D-Teams in Biotech and Pharma-Industry with in-vivo tracking of several compounds, drug carriers and nanoparticles without depth or time limitation. So, it is possible to use new analytical studies that can help to reduce the costs of R&D departments, shorten the time required for preclinical research, reduce the number of animal experiments, and increase the chances of obtaining approval by Regulatory Authorities. The studies with focus around distribution-, efficacy- and safety are customized according to the requirements of the questions being asked.
Marc Jopek has been working for over 13 years in various and international positions in the medical technology, healthcare IT and pharmaceutical industries (last position as Head of Market Access at Bayer Pharmaceutical Germany). There he has mainly built up or developed new business areas. He is currently managing director of the start-up axiom insights GmbH, which aims to establish itself in the market as a CRO for pharmaceutical and biotech companies. The company's offering focuses mainly on analytical studies which, based on an extended and patented X-ray fluorescence Imaging method, can provide in-vivo data for preclinical research that were not previously available. Based on these new data, the development of pharmaceuticals will be faster, more efficient and with less risk.
Website